News >

Abiraterone Associated With Improved PROs in Metastatic Prostate Cancer

Jason Harris
Published: Tuesday, Jan 16, 2018

Kim N. Chi, MD

Kim N. Chi, MD
Men with newly diagnosed metastatic castration-naïve prostate cancer in the global LATITUDE trial reported clinical improvements in pain progression, prostate cancer symptoms, fatigue, functional decline, and overall health-related quality of life (HR-QOL) following treatment with abiraterone acetate (Zytiga) plus prednisone.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x